KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Research & Development (2016 - 2022)

Historic Research & Development for TherapeuticsMD (TXMD) over the last 12 years, with Q3 2022 value amounting to $1.1 million.

  • TherapeuticsMD's Research & Development fell 3071.65% to $1.1 million in Q3 2022 from the same period last year, while for Sep 2022 it was $5.5 million, marking a year-over-year decrease of 3161.29%. This contributed to the annual value of $7.1 million for FY2021, which is 3207.44% down from last year.
  • According to the latest figures from Q3 2022, TherapeuticsMD's Research & Development is $1.1 million, which was down 3071.65% from $1.6 million recorded in Q2 2022.
  • TherapeuticsMD's Research & Development's 5-year high stood at $7.0 million during Q1 2018, with a 5-year trough of $1.1 million in Q3 2022.
  • For the 5-year period, TherapeuticsMD's Research & Development averaged around $3.6 million, with its median value being $2.7 million (2020).
  • Per our database at Business Quant, TherapeuticsMD's Research & Development skyrocketed by 421.75% in 2018 and then crashed by 5029.11% in 2020.
  • TherapeuticsMD's Research & Development (Quarter) stood at $6.8 million in 2018, then tumbled by 34.37% to $4.4 million in 2019, then plummeted by 45.98% to $2.4 million in 2020, then plummeted by 40.69% to $1.4 million in 2021, then decreased by 21.69% to $1.1 million in 2022.
  • Its Research & Development was $1.1 million in Q3 2022, compared to $1.6 million in Q2 2022 and $1.4 million in Q1 2022.